Department of Cardiology, University Hospital Basel, University of Basel, Petersgraben 4, CH-4031, Basel, Switzerland.
Curr Cardiol Rep. 2021 Oct 14;23(11):173. doi: 10.1007/s11886-021-01586-0.
In the interventional treatment of coronary artery disease, new-generation drug-eluting stents (DES) currently are the standard treatment. In addition, drug-coated balloons (DCB) are a well-established option for the treatment of in-stent restenosis in both bare-metal stents (BMS) and DES, where DCBs deliver an antiproliferative drug without the necessity of re-implanting a stent. Since the field of use for DCB has increasingly been extended to other indications such as de novo lesions in small vessel disease (SVD), a review of literature may be useful.
Recent randomized trial data show good efficacy and safety for DCB in de novo lesions, especially in small coronary arteries, and confirm long-term clinical efficacy and safety up to three years. DCB are an attractive and safe option in the treatment of de novo lesions in SVD.
在冠状动脉疾病的介入治疗中，新一代药物洗脱支架（DES）目前是标准治疗方法。此外，药物涂层球囊（DCB）是治疗裸金属支架（BMS）和 DES 内再狭窄的成熟选择，DCB 可输送抗增殖药物，而无需重新植入支架。由于 DCB 的使用范围越来越广泛，例如在小血管疾病（SVD）的新发病变中，对文献进行综述可能会有所帮助。
最近的随机试验数据表明，DCB 在新发病变中具有良好的疗效和安全性，特别是在小冠状动脉中，并证实了长达三年的长期临床疗效和安全性。在 SVD 中治疗新发病变时，DCB 是一种有吸引力且安全的选择。
